Pibrentasvir is a Hepatitis C NS5A inhibitor used to treat Hepatitis C. In combination with DB13879, pibrentastiv is a useful therapy for patients who experienced therapeutic failure from other NS5A inhibitors.
- Mechanism
- Curator reviewed · 2 references
NS5A is a phosphoprotein that plays an essential role in replication, assembly and maturation of infectious viral proteins. The basal phosphorylated form of NS5A, which is maintained by C-terminal serine cluster, is key in ensuring its interaction with the viral capsid protein, or the core protein. By blocking this interaction, pibrentasvir inhibits the assembly of proteins and production of mature HCV particles. NS5A also interacts with viral and cellular proteins to form the HCV replicase complex, and supports the RNA replication of HCV.
- Primary indication
- Indicated for the treatment of adult patients with acute and chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).Curator reviewed · 27 structured indications
- Formula / weight
- C57H65F5N10O8 · 1113.201 g/mol (avg)
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2020
- Code names
- A-1325912.0 · ABT-530
- Brand names
Resolves to
VJYSBPDEJWLKKJ-NLIMODCCSA-NSMILESCO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1FWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Pibrentasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account